Disappointing durable remission rates in complex Crohn's disease fistula

Inflammatory Bowel Diseases

Volumn 20, Issue 11, 2014, Pages 2022-2028

  Molendijk, Ilse ^a   Nuij, Veerle J A A ^b   Van Der Meulen De Jong, Andrea E ^a   Van Der Woude, C Janneke ^b  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Complex perianal fistulas; Crohn's disease; Healing

Indexed keywords

ANTIBIOTIC AGENT; IMMUNOSUPPRESSIVE AGENT; STEROID; TUMOR NECROSIS FACTOR INHIBITOR; GASTROINTESTINAL AGENT; MONOCLONAL ANTIBODY;

ADULT; AGED; ANTIBIOTIC THERAPY; ANUS FISTULA; ARTICLE; CHILD; COLON RESECTION; COLON SURGERY; COMPLEX PERIANAL FISTULIZING CROHN DISEASE; CROHN DISEASE; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PHYSICAL EXAMINATION; PRIORITY JOURNAL; RECTUM DISEASE; RECTUM RESECTION; RECURRENCE RISK; RELAPSE; REMISSION; STEROID THERAPY; STOMA; ADOLESCENT; CLINICAL TRIAL; COMPLICATION; DRAINAGE; FISTULA; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; PRESCHOOL CHILD; PROGNOSIS; RECURRENT DISEASE; RETROSPECTIVE STUDY; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; CHILD; CHILD, PRESCHOOL; COMBINED MODALITY THERAPY; CROHN DISEASE; DRAINAGE; FEMALE; FISTULA; FOLLOW-UP STUDIES; GASTROINTESTINAL AGENTS; HUMANS; MALE; MIDDLE AGED; PROGNOSIS; RECURRENCE; REMISSION INDUCTION; RETROSPECTIVE STUDIES; YOUNG ADULT;

EID: 84925663911     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1097/MIB.0000000000000148     Document Type: Article

References (37)

1. Abraham C, Cho JH. Inflammatory bowel disease. N Engl J Med. 2009; 361:2066-2078.
2. Van Assche G, Dignass A, Panes J, et al. The second European evidencebased consensus on the diagnosis and management of Crohn's disease: definitions and diagnosis. J Crohns Colitis. 2010;4:7-27.
3. Subasinghe D, Nawarathna NM, Samarasekera DN. Disease characteristics of inflammatory bowel disease (IBD): findings from a tertiary care centre in South Asia. J Gastrointest Surg. 2011;15:1562-1567.
4. Baumgart DC, Sandborn WJ. Inflammatory bowel disease: clinical aspects and established and evolving therapies. Lancet. 2007;369:1641-1657.
5. Kamm MA, Ng SC. Perianal fistulizing Crohn's disease: a call to action. Clin Gastroenterol Hepatol. 2008;6:7-10.
6. Hellers G, Bergstrand O, Ewerth S, et al. Occurrence and outcome after primary treatment of anal fistulae in Crohn's disease. Gut. 1980;21: 525-527.
7. Schwartz DA, Loftus EV Jr, Tremaine WJ, et al. The natural history of fistulizing Crohn's disease in Olmsted County, Minnesota. Gastroenterology. 2002;122:875-880.
8. Ingle SB, Loftus EV Jr. The natural history of perianal Crohn's disease. Dig Liver Dis. 2007;39:963-969.
9. Bell SJ, Williams AB, Wiesel P, et al. The clinical course of fistulating Crohn's disease. Aliment Pharmacol Ther. 2003;17:1145-1151.
10. Platell C, Mackay J, Collopy B, et al. Anal pathology in patients with Crohn's disease. Aust N Z J Surg. 1996;66:5-9.
11. Lockhart-Mummery HE. Symposium. Crohn's disease: anal lesions. Dis Colon Rectum. 1975;18:200-202.
12. Tang LY, Rawsthorne P, Bernstein CN. Are perineal and luminal fistulas associated in Crohn's disease? A population-based study. Clin Gastroenterol Hepatol. 2006;4:1130-1134.
13. Lapidus A. Crohn's disease in Stockholm County during 1990-2001: an epidemiological update. World J Gastroenterol. 2006;12:75-81.
14. Devaraj B, Khabassi S, Cosman BC. Recent smoking is a risk factor for anal abscess and fistula. Dis Colon Rectum. 2011;54:681-685.
15. Zimmerman DD. The impact of smoking on perianal disease. Dis Colon Rectum. 2011;54:658-659.
16. Thia KT, Mahadevan U, Feagan BG, et al. Ciprofloxacin or metronidazole for the treatment of perianal fistulas in patients with Crohn's disease: a randomized, double-blind, placebo-controlled pilot study. Inflamm Bowel Dis. 2009;15:17-24.
17. Vavricka SR, Rogler G. Fistula treatment: the unresolved challenge. Dig Dis. 2010;28:556-564.
18. West RL, van der Woude CJ, Hansen BE, et al. Clinical and endosonographic effect of ciprofloxacin on the treatment of perianal fistulae in Crohn's disease with infliximab: a double-blind placebo-controlled study. Aliment Pharmacol Ther. 2004;20:1329-1336.
19. Pearson DC, May GR, Fick GH, et al. Azathioprine and 6-mercaptopurine in Crohn disease. A meta-analysis. Ann Intern Med. 1995;123:132-142.
20. Dejaco C, Harrer M, Waldhoer T, et al. Antibiotics and azathioprine for the treatment of perianal fistulas in Crohn's disease. Aliment Pharmacol Ther. 2003;18:1113-1120.
21. Present DH, Rutgeerts P, Targan S, et al. Infliximab for the treatment of fistulas in patients with Crohn's disease. N Engl J Med. 1999;340:1398-1405.
22. Sands BE, Anderson FH, Bernstein CN, et al. Infliximab maintenance therapy for fistulizing Crohn's disease. N Engl J Med. 2004;350: 876-885.
23. Colombel JF, Schwartz DA, Sandborn WJ, et al. Adalimumab for the treatment of fistulas in patients with Crohn's disease. Gut. 2009;58: 940-948.
24. Schreiber S, Lawrance IC, Thomsen OO, et al. Randomised clinical trial: certolizumab pegol for fistulas in Crohn's disease-subgroup results from a placebo-controlled study. Aliment Pharmacol Ther. 2011;33:185-193.
25. Ford AC, Sandborn WJ, Khan KJ, et al. Efficacy of biological therapies in inflammatory bowel disease: systematic review and meta-analysis. Am J Gastroenterol. 2011;106:644-659, quiz.
26. Van Assche G, Dignass A, Reinisch W, et al. The second European evidence-based consensus on the diagnosis and management of Crohn's disease: special situations. J Crohns Colitis. 2010;4:63-101.
27. Dewint P, Hansen BE, Verhey E, et al. Adalimumab combined with ciprofloxacin is superior to adalimumab monotherapy in perianal fistula closure in Crohn's disease: a randomised, double-blind, placebo controlled trial (ADAFI). Gut. 2014;63:292-299.
28. Lennard-Jones JE. Classification of inflammatory bowel disease. Scand J Gastroenterol Suppl. 1989;170:2-6.
29. Sandborn WJ, Fazio VW, Feagan BG, et al. AGA technical review on perianal Crohn's disease. Gastroenterology. 2003;125:1508-1530.
30. Present DH, Korelitz BI, Wisch N, et al. Treatment of Crohn's disease with 6-mercaptopurine. A long-term, randomized, double-blind study. N Engl J Med. 1980;302:981-987.
31. Sandborn WJ, Present DH, Isaacs KL, et al. Tacrolimus for the treatment of fistulas in patients with Crohn's disease: a randomized, placebocontrolled trial. Gastroenterology. 2003;125:380-388.
32. Makowiec F, Jehle EC, Starlinger M. Clinical course of perianal fistulas in Crohn's disease. Gut. 1995;37:696-701.
33. Sandborn WJ, Feagan BG, Rutgeerts P, et al. Vedolizumab as induction and maintenance therapy for Crohn's disease. N Engl J Med. 2013;369:711-721.
34. Garcia-Olmo D, Garcia-Arranz M, Herreros D, et al. A phase I clinical trial of the treatment of Crohn's fistula by adipose mesenchymal stem cell transplantation. Dis Colon Rectum. 2005;48:1416-1423.
35. Garcia-Olmo D, Herreros D, Pascual I, et al. Expanded adipose-derived stem cells for the treatment of complex perianal fistula: a phase II clinical trial. Dis Colon Rectum. 2009;52:79-86.
36. Ciccocioppo R, Bernardo ME, Sgarella A, et al. Autologous bone marrow-derived mesenchymal stromal cells in the treatment of fistulising Crohn's disease. Gut. 2011;60:788-798.
37. de la Portilla F, Alba F, Garcia-Olmo D, et al. Expanded allogeneic adipose-derived stem cells (eASCs) for the treatment of complex perianal fistula in Crohn's disease: results from a multicenter phase I/IIa clinical trial. Int J Colorectal Dis. 2013;28:313-323.